Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Study Evaluating Safety and Tolerability of Combination Trametinib and Ruxolitinib in Patients With Advanced RAS Mutant Colorectal Cancer and Pancreatic Adenocarcinoma

NCT04303403 is registered in ClinicalTrials.gov with National Cancer Centre, Singapore as lead sponsor.

NCT NCT04303403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04303403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Study Evaluating Safety and Tolerability of Combination Trametinib and Ruxolitinib in Patients With Advanced RAS Mutant Colorectal Cancer and Pancreatic Adenocarcinoma
Lead sponsor
National Cancer Centre, Singapore
Phase
Phase 1
Overall status
Unknown status
Start date
July 31, 2018
Completion date
March 31, 2024
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, pancreatic adenocarcinoma